Novel Multifunctional Nanoplatelet Platform Optimizes Tumor Imaging and Radioligand Therapy

August 17, 2026

Science Daily USA

Overview

Scientists have developed a novel multifunctional nanoplatelet platform using a unique assembly process to create layered nanoparticles (nanoplatelets) with special structures capable of rapidly absorbing radioisotopes. This platform’s versatility allows it to accommodate a wide range of radioisotopes, expanding the toolkit for targeted radionuclide therapy (TRT) and providing a single platform for both imaging and therapeutic, or theranostic, purposes. This innovation is expected to significantly advance the precision and efficiency of cancer treatment.

In Depth

Key Findings

Scientists have developed a novel, multifunctional nanoplatelet platform that promises to revolutionize tumor imaging and cancer therapy. This platform consists of layered nanoparticles (nanoplatelets) manufactured through a unique assembly process, characterized by a special structure capable of rapidly and efficiently absorbing various radioisotopes. This versatility significantly expands the options for targeted radionuclide therapy (TRT), providing a single platform that serves both imaging and therapeutic purposes, as well as combined diagnostic and therapeutic (theranostic) applications. This innovation marks a critical step forward in advancing precise and personalized treatment strategies for cancer patients.

Technical / Clinical Details

The developed nanoplatelets are designed with a layered structure and surface properties that enable efficient adsorption and retention of radioisotopes. This unique assembly process allows for the production of nanoplatelets with uniform size and shape, which helps in predicting their in vivo behavior. The nanoplatelets offer several advantages:

Broad Radioisotope Compatibility: The ability to flexibly load different types of radioisotopes (e.g., diagnostic ⁶⁸Ga, therapeutic ¹⁷⁷Lu) allows clinicians to select the optimal nuclide based on specific tumor types or patient conditions. This promotes the personalization of TRT.
Highly Efficient Tumor Targeting: Nanoplatelets can be modified with ligands that target specific biomarkers or receptors (e.g., folate receptors) present in the tumor microenvironment. This ensures selective concentration of the therapeutic agent in tumor tissue, maximizing therapeutic efficacy while minimizing radiation exposure to healthy tissues.
Theranostic Functionality: The capability to perform both diagnosis and therapy with the same platform is extremely advantageous in cancer treatment. For example, diagnostic radioisotopes loaded onto nanoplatelets can first precisely locate and size tumors, followed by targeted therapy using the same nanoplatelets loaded with therapeutic radioisotopes. This enables real-time monitoring of treatment efficacy and optimization of treatment plans.

Traditional radiopharmaceuticals often face challenges such as low specificity, rapid systemic clearance, or non-specific accumulation in organs. This nanoplatelet platform aims to overcome these issues, striving to achieve a higher therapeutic index (ratio of therapeutic effect to side effects).

Background & Context

Cancer remains one of the leading causes of death globally, necessitating the development of more effective treatments with fewer side effects. Radionuclide therapy (TRT) is a modality gaining attention in cancer treatment, destroying cancer cells from within by directly delivering radionuclides to tumors. However, the scope of TRT has been limited by the types of radionuclides that can be used and the efficiency of delivery to tumors. This nanoplatelet platform has the potential to break through these limitations, significantly enhancing the clinical utility of TRT. The fusion of nanotechnology and nuclear medicine is poised to profoundly transform cancer treatment paradigms.

Strategic Significance & Outlook

This multifunctional nanoplatelet platform will significantly impact the future of cancer treatment. Future work is expected to include further evaluation of efficacy and safety in preclinical models, assessment of applicability to different tumor types, and eventual transition to clinical trials. Scaling up manufacturing processes and improving cost-efficiency will also be crucial for commercialization. If this technology becomes widely available, personalized TRT could become a standard part of cancer treatment, contributing to improved patient survival rates and quality of life.

Source: https://www.azonano.com/news.aspx?newsID=41795

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.